Utility of the Sendai Consensus Guidelines for Branch-Duct Intraductal Papillary Mucinous Neoplasms: A Systematic Review

Journal of Gastrointestinal Surgery

Volumn 18, Issue 7, 2014, Pages 1350-1357

  Goh, Brian K P ^a,b   Tan, Damien M Y ^a   Ho, Mac M F ^c   Lim, Tony K H ^a   Chung, Alexander Y F ^a   Ooi, London L P J ^a,b  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Guidelines; Intraductal papillary mucinous neoplasm; IPMN; Pancreatic cystic neoplasm; Sendai

Indexed keywords

ADENOCARCINOMA, MUCINOUS; CANCER STAGING; CARCINOMA, PANCREATIC DUCTAL; CONSENSUS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MALE; MORTALITY; PANCREAS RESECTION; PANCREATIC NEOPLASMS; PATHOLOGY; PRACTICE GUIDELINE; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; STANDARDS; SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION;

ADENOCARCINOMA, MUCINOUS; CARCINOMA, PANCREATIC DUCTAL; CONSENSUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATECTOMY; PANCREATIC NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84902547252     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-014-2510-8     Document Type: Article

References (44)

1. Spinelli KS, Fromwiller TE, Daniel RA, Kiely JM, Nakeeb A, Komorowski RA, Wilson SD, Pitt HA. Cystic pancreatic neoplasm. Observe or operate. Ann Surg 2004;239: 651-659.
2. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6: 17-12.
3. Goh BK, Tan YM, Cheow PC, Chung YF, Chow PK, Wong WK, Ooi LL. Cystic lesions of the pancreas: an appraisal of an aggressive resectional policy adopted at a single institution during 15 years. Am J Surg 2006;192: 148-54.
4. Goh BK, Tan YM, Chung YF, et al. Pancreatic cysts: a proposed management algorithm based on current evidence. Am J Surg 2007;193(6): 749-55.
5. Goh BK, Tan YM, Cheow PC, Chung YF, Chow PK, Wong WK, Ooi LL. Cystic neoplasms of the pancreas with mucin-production. Eur J Surg Oncol 2005;31: 282-287.
6. Kobari M, Egawa S, Shibuya K, et al. Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management. Arch Surg 1999;134: 1131-36.
7. Terris B, Ponsot P, Paye F, et al. Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol 2000;24: 1372-77.
8. Pelaez-Luna M, Chari ST, Smyrk TC, et al. Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J Gastroenterol 2007;102: 1759-64.
9. Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12: 183-97.
10. Tang RS, Weinberg B, Dawson DW, et al. Evaluation of guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol 2008;6: 815-19.
11. Fritz S, Klauss M, Bergmann F, et al. Small (Sendai negative) branch-duct IPMNs: not harmless. Ann Surg 2012: 256: 313-20.
12. Matsumoto T, Aramaki M, Yada K, et al. Optimal management of the branch duct type intraductal papillary mucinous neoplasms of the pancreas. J Clin Gastroenterol 2003;36: 261-65.
13. Sugiyama M, Izumisato Y, Abe N, et al. Predictive factors for malignancy in intraductal papillary-mucinous tumors of the pancreas. Br J Surg 2003;90: 1244-49.
14. Lee CJ, Scheiman J, Anderson MA, et al. Risk of malignancy in resected cystic tumors of the pancreas ≤3 cm in size: is it safe to observe asymptomatic patients? A multi-institutional report. J Gastrointestin Surg 2008;12: 234-242.
15. Mimura T, Masuda A, Matsumoto I, et al. Predictors of malignant intraductal papillary mucinous neoplasm of the pancreas. J Clin Gastroenterol 2010;44(9): e224-29.
16. Kim KW, Park SH, Pyo J, et al. Imaging features to distinguish malignant and benign branch-duct type intraductal papillary mucinous neoplasms of the pancreas. A meta-analysis. Ann Surgery 2014;259: 72-81.
17. Jang JY, Kim SW, Lee SE, et al. Treatment guidelines for branch duct type intraductal papillary mucinous neoplasms of the pancreas: when can we operate and observe. Ann Surg Oncol 2008;15(1): 199-205.
18. Anand N, Sampath K, Wu Bu. Cyst features and risk of malignancy in intraductal papillary mucinous neoplasms of the pancreas: a meta-analysis. Clin Gastro Hepatol 2013;11(8): 913-21.
19. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. BMJ 2009;339.
20. Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004;28: 977-87.
21. Adsay NV, Fukushima N, Furukawa T, Hruban RH, Klimstra DS, Kloppel G, et al. Intraductal neoplasm of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumors of the digestive system. Lyon WHO Press; 2010. p. 304-13.
22. Rodriguez JR, Salvia R, Crippa S, et al. Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology 2007;133: 72-9.
23. Nagai K, Doi R, Ito T, et al. Single-institution validation of the international consensus guidelines for treatment of branch duct intraductal papillary mucinous neoplasms of the pancreas. J Hepatobiliary Pancreat Surg 2009;16: 353-58.
24. Sawhney MS, Al-Bashir S, Cury MS, Brown A, Chuttani R, Pleskow DK, Callery MP, Vollmer CM. International Consensus guidelines for surgical resection of mucinous neoplasms cannot be applied to all cystic lesions of the pancreas. Clin Gastroenterol Hepatol 2009;7: 1373-76.
25. Pedrazzoli S, Sperti C, Pasquali C, Bissoli S, Chierichetti F. Comparison of international consensus guidelines versus 18-FDG PET in detecting malignancy of intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2011;254: 971-6.
26. Sadakari Y, Ienaga J, Kobayashi K, et al. Cyst size indicates malignant transformation in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural nodules. Pancreas 2010;39(3): 232-36.
27. Woo SM, Ryu JK, Lee SH, et al. Branch duct intraductal papillary mucinous neoplasms in a retrospective series of 190 patients. Br J Surg 2009;96: 405-11.
28. Cone MM, Rea JD, Diggs BS, et al. Predicting malignant intraductal papillary mucinous neoplasm: a single center review. Am J Surg 2011;201: 575-79.
29. Baiocchi GL, Bertagna F, Gheza F, et al. Searching for indicators of malignancy in pancreatic intraductal papillary mucinous neoplasms: the value of 18FDG-PET confirmed. Ann Surg Oncol 2012;19: 3574-80.
30. Goh BK, Thng CH, Tan DM, et al. Evaluation of the Sendai and 2012 International Consensus Guidelines based on initial cross-sectional imaging findings for the management of mucinous cystic lesions of the pancreas: a single institution experience with 114 surgically-treated patients. Am J Surg 2014 Jan 17. doi: 10. 1016/j. amjsurg. 2013. 09. 031.
31. Maguchi H, Tanno S, Mizuno N, et al. Natural history of branch-duct intraductal papillary mucinous neoplasm in Japan. Pancreas 2011;40(3): 364-70.
32. Salvia R, Crippa S, Falconi M, et al. Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Gut 2007;56: 1086-90.
33. Levy P, Jouannaud V, O'Toole D, et al. Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. Clin Gastroenterol Hepatol 2006;4: 460-68.
34. Correa-Gallego C, Brennan MF, Fong Y, et al. Liberal resection for (presumed) Sendai negative branch-duct intraductal papillary mucinous neoplasms-also not harmless. Ann Surg 2013 Aug 23.
35. Sahora K, Mino-Kenudson M, Brugge W, et al. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg 2013;258(3): 466-75.
36. Goh BK. Sendai Consensus Guidelines for branch-duct IPMN: guidelines are just guidelines. Ann Surg 2014 Jan 16.
37. Moriya T, Hashimoto, Traverso LW. The duration of symptoms predicts the presence of malignancy in 210 resected cases of pancreatic intraductal papillary mucinous neoplasms. J Gastrointest Surg 2011;15: 762-71.
38. Cone MM, Rea JD, Diggs BS, et al. Endoscopic ultrasound may be unnecessary in the preoperative evaluation of intraductal papillary mucinous neoplasm. HPB (Oxford) 2011;13: 112-116.
39. Gerke H, Jaffe TA, Mitchell RM, et al. Endoscopic ultrasound and computer tomography are inaccurate methods of classifying cystic pancreatic lesions. Dig Liver Dis 2006;38: 39-44.
40. Brugge WR. Evaluation of pancreatic cystic lesions with EUS. Gastrointest Endosc 2004;59: 698-707.
41. Fritz S, Hackert T, Hinz U, et al. Role of serum carbohydrate 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg 2011;98: 104-110.
42. Goh BK, Tan YM, Thng CH, et al. How useful are clinical, biochemical, and cross-sectional imaging features in predicting potentially malignant and malignant cystic lesions of the pancreas? Results from a single institution experience with 220 surgically treated patients. J Am Coll Surg 2008;206(1): 17-27.
43. Park WG, Wu M, Bowen R, et al. Metabolomic-derived novel cyst fluid biomarkers for pancreatic cysts: glucose and kynurenine. Gastrointest Endosc 2013;78(2): 295-302.
44. Khalid A, Zahid M, Finkelstein SD, et al. Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of the PANDA study. Gastrointest Endosc 2009;69(6): 1095-102.